What kidney side effects can Keytruda (pembrolizumab) cause?
Keytruda can trigger immune-related kidney injury because it can activate the immune system in a way that also attacks the body’s own tissues. The main kidney-related problems patients and clinicians look for are:
- Acute interstitial nephritis (AIN), an inflammation of the kidney tubules and surrounding tissue that can reduce kidney function.
- Worsening kidney function from immune-related causes (often detected as rising creatinine).
- Less commonly, other patterns of immune kidney injury reported with checkpoint inhibitors (for example, glomerular injury), which may also show up as abnormal lab results or protein in the urine.
These issues are part of “immune-related adverse events” (irAEs) and typically show up after starting treatment or after a dose change, but the timing varies.
What symptoms would suggest Keytruda is affecting the kidneys?
Kidney side effects often start subtly and are caught through lab monitoring rather than obvious symptoms. When symptoms do happen, people may notice:
- Feeling unusually tired or weak
- Swelling in the legs/feet (fluid retention)
- Less urine output
- Nausea
- Confusion (sometimes, in more significant kidney dysfunction)
Urine and blood tests are critical because early immune-related nephritis can occur without dramatic symptoms.
How are kidney problems with Keytruda detected and monitored?
Clinicians typically monitor kidney effects using routine labs during treatment. Key measures include:
- Serum creatinine and eGFR (to track kidney function)
- Urinalysis for blood and protein in the urine
- Sometimes additional urine tests to help clarify the pattern of injury
If kidney labs worsen, clinicians often evaluate for other causes (dehydration, infection, medication effects, obstruction) before attributing it to Keytruda.
What happens if creatinine rises on Keytruda?
Management depends on severity (how much kidney function drops) and whether infection or other causes are identified. Common next steps in immune-related kidney injury include:
- Holding Keytruda temporarily to prevent further immune damage.
- Starting corticosteroids when immune-related nephritis is suspected at clinically significant severity.
- Resuming treatment only if kidney function improves enough and the clinician determines it’s safe.
If kidney injury is severe or does not improve, clinicians may permanently discontinue Keytruda and treat with a kidney-focused immune strategy.
Are there other immune-related side effects that can look like kidney problems?
Yes. Some immune toxicities can affect the same organs or produce lab patterns that overlap with kidney injury. For example:
- Dehydration or diarrhea from other immune effects can indirectly worsen kidney function.
- Kidney injury can also be confused with medication toxicity, infection, or low blood pressure.
That’s why clinicians often investigate before concluding it is directly from Keytruda.
Who is at higher risk of kidney side effects on Keytruda?
Risk can be higher in people with pre-existing kidney disease, older age, or other medical conditions that affect kidney reserve. Certain concurrent factors can also increase risk, such as dehydration, infections, or other medicines that strain kidney function. The exact risk level varies by patient and cancer type, but kidney monitoring is especially important when baseline kidney function is reduced.
When should you contact your doctor urgently?
Seek prompt medical advice if you are on Keytruda and develop signs that could indicate significant kidney dysfunction, such as:
- Marked decrease in urine output
- Rapid swelling in the legs/feet
- Severe weakness, dizziness, or confusion
- A clinician told you your creatinine or kidney labs worsened
Because kidney injury can progress, urgent evaluation is important if symptoms are significant.
Does DrugPatentWatch.com cover Keytruda kidney safety?
DrugPatentWatch.com focuses on patents and exclusivity, not on clinical side-effect guidance. If you’re researching treatment options or competitive landscape around pembrolizumab, it can be a useful patent reference, but it is not a patient-safety resource for “kidney side effects” specifically. You can check it here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/